Abstracts tagged "Wegener’s granulomatosis"

Abstract Number: 893 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Belimumab in Combination with Azathioprine for Remission Maintenance in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: A Multicenter Randomized, Placebo-Controlled Study
David Jayne¹, Daniel Blockmans², Raashid Luqmani³, Beulah Ji⁴, Yulia Green⁵, Leanne Hall⁶, David Roth⁷ and Peter A. Merkel⁸, ¹Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, ³Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁴GSK Stockley Park, Uxbridge, United Kingdom, ⁵GSK Stockley Park, Stockley Park, United Kingdom, ⁶GSK Stevenage, Stevenage, United Kingdom, ⁷GSK Collegeville, Collegeville, PA, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, MN
Background/Purpose: GPA (Wegener’s) and MPA are organ- and life-threatening systemic vasculitides characterized by the presence of ANCA-associated vasculitis (AAV), implicating B cells in disease pathogenesis.…
Abstract Number: 1010 • 2017 ACR/ARHP Annual Meeting
Identification of Circulating Biomarkers of Disease Activity and Organ Involvement in ANCA-Associated Vasculitis By Targeted Proteomics
Jun Ishizaki¹, Ayako Takemori², Koichiro Suemori¹, Takuya Matsumoto¹, Yoko Akita¹, Masaki Yasukawa¹, Nobuaki Takemori² and Hitoshi Hasegawa¹, ¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ²Division of Proteomics Research, Proteo-Science Center, Ehime University, Ehime, Japan
Background/Purpose: Targeted proteomics, which involves quantitative analysis of targeted proteins using selected reaction monitoring (SRM) mass spectrometry, has emerged as a new methodology for discovery…
Abstract Number: 1757 • 2017 ACR/ARHP Annual Meeting
Rituximab for Induction and Maintenance Therapy of Granulomatosis with Polyangiitis: A Single-Center Cohort Study on 114 Patients
Xavier Puéchal¹, Michele Iudici¹, Ana Luisa Calich², Alexandre Vivot³, Benjamin Terrier⁴, Alexis Regent¹, Pascal Cohen⁴, Claire Le Jeunne⁴, Luc Mouthon⁵, Philippe Ravaud⁶ and Loïc Guillevin for the French Vasculitis Study Group⁷, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Universidade Federal de São Paulo, Hospital São Paulo, São Paulo, Brazil, ³Epidemiology, Hotel Dieu, Paris, France, ⁴Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁵Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, ⁶Paris Hotel Dieu, Paris, France, ⁷Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France
Background/Purpose: Randomized–controlled trials (RCTs) showed rituximab’s (RTX) noninferiority to cyclophosphamide for induction therapy of severe ANCA-associated vasculitides and significantly lower relapse rate than azathioprine maintenance.…
Abstract Number: 1765 • 2017 ACR/ARHP Annual Meeting
Validation of the ACR EULAR Provisional 2017 Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Patients with ANCA Associated Vasculitis
Aman Sharma¹, Adarsh MB², Shankar Naidu³, Manish Rathi⁴, Benzeeta Pinto⁵, Varun Dhir⁶, Roshan Verma⁷, Kusum Sharma⁸, Ritambhra Nada⁹, Sanjay Jain⁵ and Ranjana Minz¹⁰, ¹Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine, PGIMER, Chandigarh, India, ³PGIMER, cHANDIGARH, India, ⁴Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁵PGIMER, CHANDIGARH, India, ⁶Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁷PGIMER, Chandigarh, India, ⁸Department of Medical Microbiology,, PGIMER,, Chandigarh, India, ⁹Histopathology, Professor, Chandigarh, India, ¹⁰Department of Immunopathology,, PGIMER,, Chandigarh, India
Background/Purpose: The purpose of this study was to validate the recently proposed ACR EULAR 2017 classification criteria of GPA in a real life cohort of…
Abstract Number: 1770 • 2017 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients: Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management
Priya Chokshi¹, Olufemi Aina², Naveed Masani², Melissa Fazzari³, Elise Belilos¹, Kristina Belostocki¹, Gary Rosenblum¹, Tobin Abraham⁴, Daniil Shimonov⁴, Zinal Patel⁴ and Steven E. Carsons¹, ¹Rheumatology, NYU Winthrop Hospital, Mineola, NY, ²Nephrology, NYU Winthrop Hospital, Mineola, NY, ³Biostatistics, NYU Winthrop Hospital, Mineola, NY, ⁴Medicine, NYU Winthrop Hospital, Mineola, NY
Background/Purpose: ANCA-associated vasculitis (AAV) is a cause of multi-organ disease in all ages, but peaks at ages 65-74. Limited data is available on the characteristics…
Abstract Number: 1930 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis
Matthew D. Cascino¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁶, Cees G.M. Kallenberg⁷, E. William St Clair⁸, Paul A. Monach⁹, John H. Stone¹⁰ and Paul Brunetta¹¹, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Mayo Clinic, Rochester, MN, ³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Duke University Medical Center, Durham, NC, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹Genentech, Inc., South San Francisco, CA
Background/Purpose: Factors associated with cumulative glucocorticoid exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) have not previously been described. We examined the association…
Abstract Number: 1936 • 2016 ACR/ARHP Annual Meeting
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study
Patompong Ungprasert¹, Cynthia S. Crowson², Rodrigo Cartin-Ceba³, James A. Garrity⁴, Wendy M. Smith⁵, Ulrich Specks⁶, Eric L. Matteson¹ and Ashima Makol⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Ophthalmology, Mayo Clinic, Rochester, MN, ⁵Department of Ophthalmology, Mayo Clinic, Rochester, MN, ⁶Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is…
Abstract Number: 1948 • 2016 ACR/ARHP Annual Meeting
Evaluation of Body Composition Parameters in Granulomatosis with Polyangiitis: Association of Fat Mass Parameters with Disease Activity and Inflammatory Markers
Mariana O Perez¹, Valeria F Caparbo², Mauricio Levy-Neto² and Rosa M R Pereira², ¹Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Granulomatosis with polyangiitis (GPA, Wegener´s) patients are more exposed to traditional cardiovascular risk factor, including obesity. In rheumatic diseases, inflammation has been associated with…
Abstract Number: 1954 • 2016 ACR/ARHP Annual Meeting
Clinical Features and Long Term Outcome of 105 Patients of Granulomatosis with Polyangiitis: A Single Centre Experience from North India
Aman Sharma¹, Shankar Naidu², Manish Rathi³, Benzeeta Pinto⁴, Kusum Sharma⁵, Varun Dhir⁶, Ritambhra Nada⁷, Ranjana Minz⁸ and Surjit Singh⁹, ¹Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, cHANDIGARH, India, ³Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴PGIMER, CHANDIGARH, India, ⁵Department of Medical Microbiology,, PGIMER,, Chandigarh, India, ⁶Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁷Histopathology, Professor, Chandigarh, India, ⁸Department of Immunopathology,, PGIMER,, Chandigarh, India, ⁹Department of Internal Medicine,, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: The published Indian data on Granulomatosis with Polyangiitis (GPA) is sparse and only in the form of few small case series. The purpose of this study…
Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting
Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database
Sirada Panupattanapong¹, Anthony R. French², Andrew J. White², Margaret A. Olsen³, Maya Rendulic⁴ and Mary E. Hartman⁵, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Division of Pediatric Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ³Division of Infectious Disease, Washington University School of Medicine, St. Louis, MO, ⁴Center for Administrative Data Research, Washington University School of Medicine, St. Louis, MO, ⁵Division of Pediatric Critical Care Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…
Abstract Number: 877 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study
Ju Ann¹, Hyon K. Choi², Sharan K. Rai³, Eric C. Sayre⁴ and J Antonio Avina-Zubieta^5,6, ¹Experimental Mediine, University of British Columbia, Richmond, BC, Canada, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁶Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is associated with an increased risk of mortality. However, recent mortality trends in GPA are largely unknown, particularly in the…
Abstract Number: 888 • 2015 ACR/ARHP Annual Meeting
Plasma Exchanges to Treat Primary Systemic Necrotizing Vasculitides: Data from a French Nationwide Study
Gonzalo De Luna¹, Dominique Chauveau², Julien Aniort³, Pierre-Louis Carron⁴, Pierre Gobert⁵, Alexandre Karras⁶, Sylvain Adam-Marchand⁷, Francois Maurier⁸, Pierre-Yves Hatron⁹, Alexandre Mania¹⁰, Guillaume Le Guenno¹¹, Stéphane Ballly¹², Boris Bienvenu¹³, Eric Cardineau¹⁴, Tiphaine Goulenok¹⁵, Noémie Jourde-Chiche Sr.¹⁶, Maxime Samson¹⁷, Antoine Huart¹⁸, Jacques Pourrat¹⁹, Aurelien Tiple²⁰, Olivier Aumaître²¹, Xavier Puéchal²², Farhad Heshmati²³, Claire Le Jeunne²⁴, Luc Mouthon²⁵, Loïc Guillevin²⁶ and Benjamin Terrier²², ¹Medecine Interne, Cochin University Hospital, Paris, France, ²CH Toulouse, Toulouse, France, ³CHU, Clermont-Ferrand, France, ⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ⁵Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ⁶George Pompidou European Hospital, Paris, France, ⁷Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁰Hôpital Gabriel Montpied, Clermont-Ferrand, France, ¹¹Internal Medicine department, Clermont-Ferrand, France, ¹²CH, Chambéry, France, ¹³Internal Medicine, Hospital Caen, Caen, France, ¹⁴CH, Alencon, France, ¹⁵University Paris Diderot - APHP - Bichat Hospital, aris, France, ¹⁶Nephrology, Aix-Marseille Université - APHM, Marseille, France, ¹⁷Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹⁸CHU, Toulouse, France, ¹⁹Nephrology, Rangeuil Hospital, Paris, France, ²⁰Nephrology, CHU, Clermont-Ferrand, France, ²¹Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ²²Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²³Cochin Hospital, Paris, France, ²⁴Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ²⁵Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ²⁶Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Plasma exchange (PE) is usually used to treat severe primary systemic necrotizing vasculitides (SNVs) and/or virus-induced vasculitides. Only severe renal insufficiency (serum creatinine (SCR)…
Abstract Number: 1082 • 2015 ACR/ARHP Annual Meeting
ANCA-Negative and Myeloperoxidase-ANCA-Positive Patients with Granulomatosis with Polyangiitis: Clinical Manifestations and Risk of Relapse
Eli Miloslavsky¹, Na Lu², Sebastian Unizony³, Hyon K. Choi³, Peter A. Merkel⁴, Philip Seo⁵, Robert F. Spiera⁶, Carol A. Langford⁷, Gary S. Hoffman⁷, Cees Kallenberg⁸, E. William St.Clair⁹, Nadia Tchao¹⁰, Fernando Fervenza¹¹, Paul A. Monach¹², Ulrich Specks¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology/Clin Immunol AA21, Univer Med Center Groningen, Groningen, Netherlands, ⁹Rheumatology and Immunology, Duke University, Durham, NC, ¹⁰ITN, San Francisco, CA, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Recent studies in ANCA-associated vasculitis (AAV) have suggested that classification based on ANCA type (PR3 versus MPO) may represent a more clinically relevant division…
Abstract Number: 1270 • 2015 ACR/ARHP Annual Meeting
Low Socioeconomic Status As a Predictor of Long-Term Direct Medical Costs Following Diagnosis of Granulomatosus with Polyangiitis: A General Population-Based Cohort Study
Natalie McCormick¹, Carlo Marra² and J Antonio Avina-Zubieta³, ¹Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Estimates of the healthcare costs of Granulomatosus with polyangiitis (GPA) and predictors of costs are scarce. In particular, while socioeconomic status (SES) is associated…
Abstract Number: 1944 • 2015 ACR/ARHP Annual Meeting
Dalazatide Modulates CD4+ Effector Memory T-Cell Activity of Patients with Granulomatosis with Polyangiitis in Vitro
Lucas L. Lintermans¹, Ernesto J. Muñoz-Elías², Minke G. Huitema¹, Elisabeth Brouwer¹, Abraham Rutgers¹, Coen A. Stegeman³, Peter Heeringa⁴ and Wayel H. Abdulahad¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Translational Immunology & Preclinical Development, Kineta, Inc., Seattle, WA, ³Nephrology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: There is substantial evidence that CD4+ effector memory T (TEM) cells play a crucial role in the pathogenesis of Granulomatosis with polyangiitis (GPA). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].